Literature DB >> 22342602

Endogenous bile acid disposition in rat and human sandwich-cultured hepatocytes.

Tracy L Marion1, Cassandra H Perry, Robert L St Claire, Kim L R Brouwer.   

Abstract

Sandwich-cultured hepatocytes (SCH) are used commonly to investigate hepatic transport protein-mediated uptake and biliary excretion of substrates. However, little is known about the disposition of endogenous bile acids (BAs) in SCH. In this study, four endogenous conjugated BAs common to rats and humans [taurocholic acid (TCA), glycocholic acid (GCA), taurochenodeoxycholic acid (TCDCA), and glycochenodeoxycholic acid (GCDCA)], as well as two BA species specific to rodents (α- and β-tauromuricholic acid; α/β TMCA), were profiled in primary rat and human SCH. Using B-CLEAR® technology, BAs were measured in cells+bile canaliculi, cells, and medium of SCH by LC-MS/MS. Results indicated that, just as in vivo, taurine-conjugated BA species were predominant in rat SCH, while glycine-conjugated BAs were predominant in human SCH. Total intracellular BAs remained relatively constant over days in culture in rat SCH. Total BAs in control (CTL) cells+bile, cells, and medium were approximately 3.4, 2.9, and 8.3-fold greater in human than in rat. The estimated intracellular concentrations of the measured total BAs were 64.3±5.9 μM in CTL rat and 183±56 μM in CTL human SCH, while medium concentrations of the total BAs measured were 1.16±0.21 μM in CTL rat SCH and 9.61±6.36 μM in CTL human SCH. Treatment of cells for 24h with 10 μM troglitazone (TRO), an inhibitor of the bile salt export pump (BSEP) and the Na⁺-taurocholate cotransporting polypeptide (NTCP), had no significant effect on endogenous BAs measured at the end of the 24-h culture period, potentially due to compensatory mechanisms that maintain BA homeostasis. These data demonstrate that BAs in SCH are similar to in vivo, and that SCH may be a useful in vitro model to study alterations in BA disposition if species differences are taken into account.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22342602      PMCID: PMC3679176          DOI: 10.1016/j.taap.2012.02.002

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  51 in total

1.  Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate.

Authors:  C Funk; M Pantze; L Jehle; C Ponelle; G Scheuermann; M Lazendic; R Gasser
Journal:  Toxicology       Date:  2001-10-05       Impact factor: 4.221

2.  Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione.

Authors:  Maria Rius; Johanna Hummel-Eisenbeiss; Alan F Hofmann; Dietrich Keppler
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-11-10       Impact factor: 4.052

3.  Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats.

Authors:  X Liu; J P Chism; E L LeCluyse; K R Brouwer; K L Brouwer
Journal:  Drug Metab Dispos       Date:  1999-06       Impact factor: 3.922

Review 4.  Hepatic secretion of conjugated drugs and endogenous substances.

Authors:  D Keppler; J König
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

Review 5.  Hepatobiliary transporters and drug-induced cholestasis.

Authors:  Christiane Pauli-Magnus; Peter J Meier
Journal:  Hepatology       Date:  2006-10       Impact factor: 17.425

6.  Induction of the mitochondrial permeability transition as a mechanism of liver injury during cholestasis: a potential role for mitochondrial proteases.

Authors:  G J Gores; H Miyoshi; R Botla; H I Aguilar; S F Bronk
Journal:  Biochim Biophys Acta       Date:  1998-08-10

Review 7.  Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.

Authors:  Yasuhiro Masubuchi
Journal:  Drug Metab Pharmacokinet       Date:  2006-10       Impact factor: 3.614

8.  Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice.

Authors:  Mahfoud Assem; Erin G Schuetz; Markos Leggas; Daxi Sun; Kazuto Yasuda; Glen Reid; Noam Zelcer; Masashi Adachi; Stephen Strom; Ronald M Evans; David D Moore; Piet Borst; John D Schuetz
Journal:  J Biol Chem       Date:  2004-03-05       Impact factor: 5.157

9.  Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane.

Authors:  Maria Rius; Anne T Nies; Johanna Hummel-Eisenbeiss; Gabriele Jedlitschky; Dietrich Keppler
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

10.  Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis.

Authors:  Gernot Zollner; Peter Fickert; Dagmar Silbert; Andrea Fuchsbichler; Hanns Ulrich Marschall; Kurt Zatloukal; Helmut Denk; Michael Trauner
Journal:  J Hepatol       Date:  2003-06       Impact factor: 25.083

View more
  15 in total

1.  Effect of Cryopreservation on Enzyme and Transporter Activities in Suspended and Sandwich Cultured Rat Hepatocytes.

Authors:  Janneke Keemink; Neel Deferm; Tom De Bruyn; Patrick Augustijns; Thomas Bouillon; Pieter Annaert
Journal:  AAPS J       Date:  2018-02-21       Impact factor: 4.009

Review 2.  Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.

Authors:  Kyunghee Yang; Cen Guo; Jeffrey L Woodhead; Robert L St Claire; Paul B Watkins; Scott Q Siler; Brett A Howell; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2016-02       Impact factor: 3.534

Review 3.  Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management.

Authors:  M Mosedale; P B Watkins
Journal:  Clin Pharmacol Ther       Date:  2017-01-11       Impact factor: 6.875

4.  Comparative Localization and Functional Activity of the Main Hepatobiliary Transporters in HepaRG Cells and Primary Human Hepatocytes.

Authors:  Pamela Bachour-El Azzi; Ahmad Sharanek; Audrey Burban; Ruoya Li; Rémy Le Guével; Ziad Abdel-Razzak; Bruno Stieger; Christiane Guguen-Guillouzo; André Guillouzo
Journal:  Toxicol Sci       Date:  2015-02-17       Impact factor: 4.849

5.  Combination lopinavir and ritonavir alter exogenous and endogenous bile acid disposition in sandwich-cultured rat hepatocytes.

Authors:  LaToya M Griffin; Paul B Watkins; Cassandra H Perry; Robert L St Claire; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2012-10-22       Impact factor: 3.922

6.  Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures.

Authors:  Jie Liu; Hong Lu; Yuan-Fu Lu; Xiaohong Lei; Julia Yue Cui; Ewa Ellis; Stephen C Strom; Curtis D Klaassen
Journal:  Toxicol Sci       Date:  2014-07-23       Impact factor: 4.849

7.  Different dose-dependent mechanisms are involved in early cyclosporine a-induced cholestatic effects in hepaRG cells.

Authors:  Ahmad Sharanek; Pamela Bachour-El Azzi; Houssein Al-Attrache; Camille C Savary; Lydie Humbert; Dominique Rainteau; Christiane Guguen-Guillouzo; André Guillouzo
Journal:  Toxicol Sci       Date:  2014-06-27       Impact factor: 4.849

8.  Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?

Authors:  Jason R Slizgi; Yang Lu; Kenneth R Brouwer; Robert L St Claire; Kimberly M Freeman; Maxwell Pan; William J Brock; Kim L R Brouwer
Journal:  Toxicol Sci       Date:  2015-10-26       Impact factor: 4.849

Review 9.  Evaluation of Adverse Drug Properties with Cryopreserved Human Hepatocytes and the Integrated Discrete Multiple Organ Co-culture (IdMOC(TM)) System.

Authors:  Albert P Li
Journal:  Toxicol Res       Date:  2015-06

10.  Successful mouse hepatocyte culture with sandwich collagen gel formation.

Authors:  Hyun Jung Choi; Dongho Choi
Journal:  J Korean Surg Soc       Date:  2013-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.